TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including GLP-1 therapies, to older adults. It calls for assessing function, nutrition and cognition before treatment and pairing medication with supports such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has released a clinical framework to help clinicians prescribe obesity medications to older adults with attention to age-related risks and individual priorities. Published in the Journal of the American Geriatrics Society, the case-based paper includes guidance on assessing function, nutrition and cognition before treatment, including with GLP-1 medicines.
The paper, developed by the AGS Healthy Aging Special Interest Group, applies the Geriatrics 5Ms Framework—Mind, Mobility, Medications, Multicomplexity and Matters Most—to incretin-based obesity treatment. The authors present the approach through a series of cases intended to help clinicians account for an older patient’s health and circumstances rather than focusing on weight alone.
The framework highlights concerns including frailty, sarcopenia and loss of lean muscle, as well as malnutrition and dehydration. It recommends assessing functional status, nutritional adequacy and cognitive impairment before starting therapy. The paper also advises pairing medication with supportive measures, including resistance training and adequate dietary protein.
For some patients, the authors say care may be best delivered by a team that includes professionals such as a registered dietitian, physical therapist, fitness trainer and behavioral health specialist. The article is by Elias M. Wisdom and co-authors and was published in 2026. Its DOI is 10.1111/jgs.70769.
Balancing Weight Loss With Function
The framework addresses a practical challenge: a medicine’s potential benefits for weight management and blood sugar control must be considered alongside the health needs that can be especially important in later life. The authors describe obesity medications as offering promising benefits, while noting that older adults have been underrepresented in clinical trials. That leaves clinicians with less evidence specific to this population than they may have for other groups.
By putting mobility, nutrition, cognition and patients’ own priorities into the prescribing discussion, the 5Ms approach directs attention to outcomes beyond weight change. The recommendations also make clear that medication may not be the only component of care: maintaining strength and adequate nutrition are part of the proposed approach. The framework offers clinicians a structure for considering those issues, but the supplied report does not establish that it has been tested as a clinical intervention or that it produces particular patient outcomes.
Products Worth Considering
VEVOR Walk-In Tunnel Greenhouse with Watering System, 15 x 7 x 7 ft
Husqvarna 450 Rancher 20-Inch Gas Chainsaw
EGO Power+ Cordless Electric Leaf Blower, 880 CFM, with Two 4.0Ah Batteries (LB8803-2)
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms
The AGS framework uses the organization’s Geriatrics 5Ms to organize decisions about incretin therapy. “Mind” includes cognitive considerations; “Mobility” focuses on movement and function; “Medications” concerns treatment choices; “Multicomplexity” reflects interacting health needs; and “Matters Most” centers what is important to the individual patient. The paper uses cases to show how clinicians might apply these areas when considering obesity medicines.
The report specifically refers to GLP-1 medications, which act through gut-derived hormonal pathways, as part of the broader discussion of obesity drugs. It does not provide a medication-by-medication comparison, dosing guidance or a new drug approval. Instead, its focus is a prescribing framework for older adults and the assessments and supports the authors believe should inform care.
“Older adults are underrepresented in clinical trials.”
— The paper’s authors, as summarized by Medical Xpress
Evidence Gaps in Older Patients
The source report does not specify how widely the framework has been adopted, whether clinicians have evaluated it in practice, or what effects it has on patient outcomes. It also does not quantify how often treatment-related muscle loss, dehydration or malnutrition occurs among older adults using these medicines. The stated concern that older adults are underrepresented in trials means the paper does not resolve all questions about how benefits and risks vary with age, frailty or other health conditions.
The framework is a clinical guidance paper, not a report of a new trial or a change in medication approval. The available source does not set out a universal eligibility rule or say that every older adult should receive an obesity medication. Individual treatment decisions and the appropriate support plan remain patient- and clinician-specific.
How Clinicians May Use the Framework
The framework is now available in the Journal of the American Geriatrics Society for clinicians to consider in practice. Its case-based format is intended to help organize discussions before prescribing and to identify when additional support—such as nutrition or physical therapy input—may be useful. The source material does not announce a formal rollout, implementation schedule or follow-up study.
Further research and real-world reporting would be needed to show how the approach affects prescribing, strength, nutritional status and other outcomes for older patients. For now, the report’s central recommendation is to assess the whole patient, discuss what matters to them, and consider medication alongside appropriate supportive care.
Key Questions
Who released the framework?
The American Geriatrics Society released it. The paper was developed by the AGS Healthy Aging Special Interest Group and published in the Journal of the American Geriatrics Society.
What does the framework ask clinicians to assess before treatment?
It recommends assessing functional status, nutritional adequacy and cognitive impairment, while considering risks such as frailty, sarcopenia, lean muscle loss, malnutrition and dehydration.
Does the paper recommend medication on its own?
No. The authors recommend considering supportive measures, including resistance training and adequate dietary protein. For some older adults, they say a team-based approach may be appropriate.
Does the framework establish that obesity medicines are safe for every older adult?
No. It is a prescribing framework, not evidence that every older adult should use these medicines. The report notes that older adults are underrepresented in clinical trials and emphasizes individualized assessment.
Source: medicalxpress.com
